Beam Therapeutics (MEX:BEAM) Beta: 0.1339 (As of Jun. 26, 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
68 GF Score
Price MXN628.46
GF Value MXN541.64
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Beta?

Beam Therapeutics MEX:BEAM 68 Beta is 0.1339 as of Jun. 26, 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 68/100 and a GF Value™ of MXN541.64 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Beam Therapeutics's Beta is 0.1339.


Beam Therapeutics  (MEX:BEAM) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Beam Therapeutics Beta Related Terms


Beam Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Beta Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.12

MEX:BEAM vs DNLI, ORKA, DYN: Beta Comparison

For the Biotechnology subindustry, Beam Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beam Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Beta falls into.


MEX:BEAM
68GF Score
Beam Therapeutics Inc MEX:BEAM
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.1339 mean?
Beam Therapeutics (MEX:BEAM) has a Beta of 0.1339 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Beam Therapeutics and its competitors.
Is Beam Therapeutics' Beta too high?
Beam Therapeutics' current Beta is 0.1339. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Beta compare to DNLI and ORKA?
Beam Therapeutics' Beta of 0.1339 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Beam Therapeutics and its competitors. Beam Therapeutics's current Beta is 0.1339. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN541.64, compared to a current price of MXN628.46 — trading 16% above its estimated fair value. The current Beta is 0.1339. Beam Therapeutics' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Beta is 0.1339 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 16% above its estimated GF Value™ of MXN541.64. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Beta: 0.1339
  • GF Value™: MXN541.64 vs. price of MXN628.46 (16% above fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score

Get the complete analysis for MEX:BEAM

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN541.64
GF Value